Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 15/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787710 | 1.00 | FFAR2 (1.00) | FFAR2RAB9ANPC1CYP1A2MAPT | |
| SCHEMBL2037008 | 1.00 | FFAR2 (1.00) | FFAR2RAB9ANPC1CYP1A2MAPT | |
| SCHEMBL2043877 | 0.80 | FFAR2 (0.64) | FFAR2RAB9ANPC1CYP1A2MAPT | |
| SCHEMBL2554297 | 0.74 | SMN1; SMN2 (0.78) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18674667 | 0.74 | SMN1; SMN2 (0.63) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29787691 | 0.74 | FFAR2 (1.00) | FFAR2 | |
| SCHEMBL2037692 | 0.74 | FFAR2 (1.00) | FFAR2 | |
| SCHEMBL2039602 | 0.73 | FFAR2 (0.59) | FFAR2MAPTSMN1; SMN2 | |
| SCHEMBL2039599 | 0.73 | FFAR2 (0.59) | FFAR2MAPTSMN1; SMN2 | |
| SCHEMBL29787736 | 0.73 | FFAR2 (0.59) | FFAR2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| EP-2513053-B1 | Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders | OGEDA SA (BE) | 2017-10-04 | — | — | EP | disclosed |